London and New York, NY., 21 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to
OKYO Pharma LTD (AIM:OKYO) publicly files a registration statement with the SEC
LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease
OKYO Pharma LTD (AIM:OKYO) Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease-
OKYO Pharma (NASDAQ: OKYO; LSE: OKYO) Interview to Air on Bloomberg U.S. on the RedChip Money Report®
NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to
Trader’s Café with Zak Mir: A Week In Small Caps, Sunday 4th September 2022
Back To School
OKYO Pharma LTD (AIM: OKYO) announces issuance of U.S. Patent No. 11,254,720
Covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain.
Traders Cafe with Zak Mir: The Top 20 Stocks For 2022 via Vox Markets
Introduction: At the time of writing the US stock market is set for its 70th record close of the year. Older market watchers will know that a wall of worry is what
Traders Cafe with Zak Mir: The Top 20 Stocks For 2022 via Vox Markets
Introduction: At the time of writing the US stock market is set for its 70th record close of the year. Older market watchers will know that a wall of worry is what
Traders Cafe with Zak Mir: The Top 20 Stocks For 2022 Countdown – 4 to 1 (Part 4) via Vox Markets
The Top 20 For 2022: Of course, at this time of the year, everyone and their mother deliver their list for the winners of the New Year, as I have in
Traders Cafe with Zak Mir: The Top 20 Stocks For 2022 Countdown – 9 to 5 (Part 3) via Vox Markets
The Top 20 For 2022: Of course, at this time of the year, everyone and their mother deliver their list for the winners of the New Year, as I have in
Traders Cafe with Zak Mir: The Top 20 Stocks For 2022 Countdown – 14 to 10 (Part 2) via Vox Markets
The Top 20 For 2022: Of course, at this time of the year, everyone and their mother deliver their list for the winners of the New Year, as I have
OKYO Pharma Limited (OKYO.L) IND filing Q3 2022 and Phase 2 initiation Q4 2022
OKYO to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients